Synthetic miR-34a against solid tumours: a predictable failure.
Sophie MocklyHervé SeitzPublished in: British journal of cancer (2022)
A prolific scientific literature attributes pro- or anti-oncogenic properties to many human microRNAs ("miRNAs"). While many of these studies are based on unpersuasive analyses, one candidate suppressor tumour miRNA, miR-34a, appeared convincing enough to be administered to human patients in a clinical trial-with disappointing outcomes. Here, we review possible reasons for that failure, and their implications for other miRNAs.
Keyphrases
- endothelial cells
- cell proliferation
- clinical trial
- long non coding rna
- end stage renal disease
- induced pluripotent stem cells
- ejection fraction
- systematic review
- newly diagnosed
- long noncoding rna
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- transcription factor
- phase ii
- weight loss
- insulin resistance